Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Bought by Principal Financial Group Inc.

Principal Financial Group Inc. boosted its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 2.8% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 20,602 shares of the biopharmaceutical company’s stock after buying an additional 558 shares during the period. Principal Financial Group Inc.’s holdings in Halozyme Therapeutics were worth $267,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. IFC Holdings Incorporated FL raised its position in shares of Halozyme Therapeutics by 0.7% in the first quarter. IFC Holdings Incorporated FL now owns 82,250 shares of the biopharmaceutical company’s stock valued at $1,063,000 after buying an additional 600 shares during the last quarter. Janney Montgomery Scott LLC increased its stake in shares of Halozyme Therapeutics by 1.0% in the first quarter. Janney Montgomery Scott LLC now owns 84,874 shares of the biopharmaceutical company’s stock valued at $1,100,000 after buying an additional 877 shares during the period. Sei Investments Co. increased its stake in shares of Halozyme Therapeutics by 0.8% in the first quarter. Sei Investments Co. now owns 309,725 shares of the biopharmaceutical company’s stock valued at $4,014,000 after buying an additional 2,605 shares during the period. Chicago Equity Partners LLC increased its stake in shares of Halozyme Therapeutics by 1.7% in the first quarter. Chicago Equity Partners LLC now owns 170,030 shares of the biopharmaceutical company’s stock valued at $2,204,000 after buying an additional 2,770 shares during the period. Finally, American International Group Inc. increased its stake in shares of Halozyme Therapeutics by 7.0% in the first quarter. American International Group Inc. now owns 67,109 shares of the biopharmaceutical company’s stock valued at $870,000 after buying an additional 4,407 shares during the period. Institutional investors own 81.49% of the company’s stock.

Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) opened at 11.90 on Friday. Halozyme Therapeutics, Inc. has a 52 week low of $8.18 and a 52 week high of $15.20. The company’s market cap is $1.59 billion. The firm’s 50-day moving average price is $13.12 and its 200 day moving average price is $13.12.

Halozyme Therapeutics (NASDAQ:HALO) last released its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.23) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.25) by $0.02. The business had revenue of $33.80 million for the quarter, compared to the consensus estimate of $31.76 million. The firm’s revenue was up 1.2% on a year-over-year basis. During the same quarter last year, the company earned ($0.21) earnings per share. On average, equities analysts predict that Halozyme Therapeutics, Inc. will post ($0.97) EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This piece of content was first reported by Transcript Daily and is owned by of Transcript Daily. If you are reading this piece of content on another domain, it was illegally copied and reposted in violation of United States & international copyright legislation. The correct version of this piece of content can be read at https://transcriptdaily.com/2017/08/13/principal-financial-group-inc-buys-558-shares-of-halozyme-therapeutics-inc-nasdaqhalo-updated.html.

Several analysts recently issued reports on the company. Piper Jaffray Companies set a $20.00 price target on Halozyme Therapeutics and gave the stock a “buy” rating in a report on Thursday. Zacks Investment Research raised Halozyme Therapeutics from a “hold” rating to a “buy” rating and set a $14.00 price target on the stock in a report on Friday. Canaccord Genuity set a $16.00 price target on Halozyme Therapeutics and gave the stock a “buy” rating in a report on Wednesday, July 26th. Jefferies Group LLC reissued an “underperform” rating and issued a $7.00 price target (up previously from $6.75) on shares of Halozyme Therapeutics in a report on Thursday. Finally, BidaskClub downgraded Halozyme Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday, July 1st. One analyst has rated the stock with a sell rating, four have assigned a hold rating and six have issued a buy rating to the company. Halozyme Therapeutics has a consensus rating of “Hold” and an average target price of $14.75.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biotechnology company focused on developing and commercializing oncology therapies. The Company operates in research, development and commercialization of human enzymes and other drug candidates. The Company’s segment also includes research and development activities and product sales of Hylenex recombinant.

Institutional Ownership by Quarter for Halozyme Therapeutics (NASDAQ:HALO)

Receive News & Ratings for Halozyme Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply